1Mackett M, Smith G L, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector [J]. Proc Natl Acad Sci USA, 1982, 93:11 287～11 425.
2Timiyasova T M, Chen B, Fodor I. Replicationdeficient vaccinia virus gene therapy vector:evaluation of exogenous gene expression mediated by PUV-inactiviated virus in glioma cell [J]. J Gene Med, 2001,3(5): 468～477.
3Nanda D, Vogels R, Havenga , et al. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex viruse-thymidine kinase [J]. Cancer Res, 2001,61(24):8 743～8 750.
4Zhang R , De Groot L J. An adenoviral vector expressing functional heterogeneous proteins herpes simplex viral thymidine kinase and human interleukin 2 has enhanced in vivo antitumor activity against medullary thyroid carcinoma [J]. Endocr Relat Cancer,2001,8(4): 315～325.
5Rubinchik S , Wang D, Yu H. et al. A complex adenovirus vector that delivers FASL-GFP with combined postate-specific and tetracycline-regulated expression [J]. Mol Ther,2001,4(5) :416～426.
6Walz C M, Correa-Ochoa M M, Muller M. et al.Adeno-associated virus type 2-induced inhibition of human papillomavirus type 18 promoter in transgenic mice [J]. Virology,2002,293(1): 172～181.
7Duverger V, Sartorius U, Klein-Bauernschimitt P, et al. Enhancement of cisplatin-induced apoptosis by infection of adeno-associated virus type 2 [J]. Int J Cancer, 2002,97(5): 706～712.
8Blank S V, Rubin S C, Coukos G, et al. Replicationselective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low dose radiation [J]. Hum Gene Ther,2002,13(5): 627～639.
9Rees R C, McArdle S, Mian S.et al. DISC-HSV as a vector for immunogene therapy for cancer [J]. Curr Opin Mol Ther ,2002,4(1): 49～53.
10Chung S M, Advani S J, Bradley J D, et al. The use of a genetically engineered herpes simplex virus (R7020) with ironing radiation for experimental hepatoma [J]. Gene Ther, 2002,9(1): 75～80.
